DENTSPLY SIRONA Inc. (BVMF:XRAY34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 10.31B -23.6% |
| Revenue (ttm) | 18.52B -1.4% |
| Net Income | -626.77M |
| EPS | -3.36 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 7.78 |
| Dividend | 0.53 (0.91%) |
| Ex-Dividend Date | Dec 23, 2025 |
| Volume | n/a |
| Open | 58.35 |
| Previous Close | 58.35 |
| Day's Range | 58.35 - 58.35 |
| 52-Week Range | 42.30 - 74.08 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as w... [Read more]
Financial Performance
In 2025, DENTSPLY SIRONA's revenue was $3.68 billion, a decrease of -2.98% compared to the previous year's $3.79 billion. Losses were -$598.00 million, -34.29% less than in 2024.
Financial numbers in USD Financial StatementsNews
Dentsply Sirona price target lowered to $11 from $13 at Barrington
Barrington lowered the firm’s price target on Dentsply Sirona (XRAY) to $11 from $13 and keeps an Outperform rating on the shares. The company’s Q3 report is “mostly disappointing,” the…
Dentsply Sirona price target lowered to $10 from $13 at Jefferies
Jefferies lowered the firm’s price target on Dentsply Sirona (XRAY) to $10 from $13 and keeps a Hold rating on the shares. Q3 sales and EPS missed consensus on continued…
Dentsply Sirona price target lowered to $14 from $17 at BofA
BofA lowered the firm’s price target on Dentsply Sirona (XRAY) to $14 from $17 and keeps a Buy rating on the shares.
Dentsply Sirona price target lowered to $11 from $12 at Morgan Stanley
Morgan Stanley analyst Erin Wright lowered the firm’s price target on Dentsply Sirona (XRAY) to $11 from $12 and keeps an Equal Weight rating on the shares. Published first on…
Dentsply Sirona price target lowered to $10 from $12 at JPMorgan
JPMorgan lowered the firm’s price target on Dentsply Sirona (XRAY) to $10 from $12 and keeps a Neutral rating on the shares.
Dentsply Sirona price target lowered to $11 from $12 at Mizuho
Mizuho lowered the firm’s price target on Dentsply Sirona (XRAY) to $11 from $12 and keeps a Neutral rating on the shares.
Dentsply Sirona price target lowered to $9 from $10 at Baird
Baird analyst Jeff Johnson lowered the firm’s price target on Dentsply S irona to $9 from $10 and keeps a Neutral rating on the shares. The firm updated its model…
DENTSPLY SIRONA Earnings Call Transcript: Q3 2026
Q3 revenue fell 7.6% reported, while adjusted EPS was $0.29 and operating cash flow declined amid working-capital pressure. FY26 guidance was cut, as early U.S. dental momentum and Wellspect growth were offset by EMEA pressures and continued investment.
DENTSPLY SIRONA Earnings release: Q3 2026
DENTSPLY SIRONA released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
DENTSPLY SIRONA Quarterly report: Q3 2026
DENTSPLY SIRONA has published its Q3 2026 quarterly earnings report on November 5, 2026.
DENTSPLY SIRONA Slides: Q3 2026
DENTSPLY SIRONA has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Dentsply Sirona reports Q3 EPS 29c, consensus 31c
Reports Q3 revenue $836M, consensus $861.65M. “We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions,” said Dan Scavilla, ...
Dentsply Sirona cuts FY26 adjusted EPS view to $1.20-$1.30 from $1.40-$1.50
Consensus $1.49. Narrows FY26 revenue view to $3.5B from $3.5B-$3.6B, consensus $3.57B. The company said, “The Company is updating its 2026 outlook to approximately $3.5 billion in net sales and…
Dentsply Sirona Reports Third Quarter 2026 Results
News Summary Q3 2026 net sales of $836 million Q3 2026 GAAP gross margin of 52.9% , GAAP diluted loss per share of ($0.01) Q3 2026 adjusted gross margin of 54.5% , adjusted EBITDA margin of 17.3% , ad...
Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Dentsply Sirona price target lowered to $13 from $15 at Barrington
Barrington lowered the firm’s price target on Dentsply Sirona (XRAY) to $13 from $15 and keeps an Outperform rating on the shares ahead of the company’s Q3 report due on…
Dentsply Sirona price target lowered to $12 from $14 at Mizuho
Mizuho lowered the firm’s price target on Dentsply Sirona (XRAY) to $12 from $14 and keeps a Neutral rating on the shares. The firm sees a “less optimistic” outlook for…
Dentsply Sirona to Host Third Quarter 2026 Conference Call on November 5
CHARLOTTE, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and l...
Dentsply Sirona price target lowered to $10 from $14 at Leerink
Leerink lowered the firm’s price target on Dentsply Sirona (XRAY) to $10 from $14 and keeps a Market Perform rating on the shares. The firm says there are very few…
Dentsply Sirona price target lowered to $12 from $14 at Piper Sandler
Piper Sandler lowered the firm’s price target on Dentsply Sirona (XRAY) to $12 from $14 and keeps a Neutral rating on the shares. The firm is updating its Dentsply model…
Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio
MÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External...
Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement
The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona's North American dealer network and giving more customers access to its products and techn...
Dentsply Sirona price target lowered to $10 from $13 at BMO Capital
BMO Capital analyst Vik Chopra lowered the firm’s price target on Dentsply Sirona (XRAY) to $10 from $13 and keeps a Market Perform rating on the shares after the management…
DENTSPLY SIRONA Transcript: 2026 Global Healthcare Conference
Leadership highlighted ongoing transformation, resource reallocation, and a 24-month turnaround plan. Strategic focus includes expanding sales channels, investing in clinical education and R&D, and enhancing digital workflows. Financially, sequential EPS growth is targeted, with long-term goals of market-level or better growth and improved cash flow.
Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference
CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global ...